Apogee releases APG777 Phase 1 data in web presentation; no specific results in 8-K

Apogee Therapeutics, Inc.

Phase 1 first-in-human data for APG777 posted to company website on March 5, 2024.
Presentation covers safety, pharmacokinetics, and biomarker data from initial cohort.
No numerical efficacy or safety figures are disclosed in the 8-K filing itself.

item 7.01 item 9.01

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-030772

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.